CG Oncology, Inc. CGON

US Biotechnology

$73.84 ▼ -1.20% ($-0.90)

📅 Earnings This Week

Open $74.35

Prev Close $74.74

Day Range $73.42 – $75.01

52W Range $35.80 – $80.97

Market Cap $6.62B

Beta 0.14

EPS (TTM) $-2.76

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-01-25
Shares Out.	88,640,000
Website	cgoncology.com/ ↗
Phone	19492886298
Employees	142
Revenue	$1.2M
Gross Profit	-$2.8M
Net Income	-$79.1M
Free Cash Flow	-$179.3M
Total Assets	$1.09B
Total Liabilities	$56.5M
Equity	$1.03B

About CG Oncology, Inc.

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology, Inc. is a publicly traded company under the ticker symbol CGON on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.